Form 13-F position report

XERIS BIOPHARMA HOLDINGS INC

Reported by Cliffwater LLC

XERS CUSIP 98422E103 Manager CIK 0001659851

Reported 263,158 shares, unchanged from the prior quarter.

Reported value 20.7%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 0.75% This manager · Q3 2026
Shares 263,158 Quarter-end amount reported
Reported value $2,515,790 Fair value at quarter end
Consecutive quarters held 2 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2026-06-30 2084211
2026-09-30 2515790

Quarterly position history

How this manager's reported quarter-end position changed over time.

2 quarters
Quarterly reported position history for XERIS BIOPHARMA HOLDINGS INC held by Cliffwater LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Unchanged 263,158 0 (0.0%) 0.75% $2,515,790 2026-11-13
Q2 2026 New 263,158 +263,158 (0.0%) 0.52% $2,084,211 2026-08-12

Who else reported the position

269 managers reported XERIS BIOPHARMA HOLDINGS INC for Q3 2026.

Managers reporting XERIS BIOPHARMA HOLDINGS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 14,659,299 +133,760 < 0.01% $140,142,897 9 qtrs
D E Shaw & Co Inc Added 7,980,158 +175,400 0.04% $76,290,311 19 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 7,710,356 +370,127 < 0.01% $73,711,003 3 qtrs
STATE STREET CORPORATION Added 5,574,524 +752,958 < 0.01% $53,292,449 20 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 4,570,751 -147,432 < 0.01% $43,704,790 21 qtrs
Nuveen LLC Reduced 4,141,888 -243,253 < 0.01% $39,596,450 7 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 2,648,881 +22,673 < 0.01% $25,323,302 3 qtrs
Rosalind Advisors Inc Reduced 2,582,647 -326,334 7.92% $24,690,105 12 qtrs
MORGAN STANLEY Added 2,580,523 +243,427 < 0.01% $24,669,808 20 qtrs
JPMorgan Chase & Co Added 2,381,573 +1,323,506 < 0.01% $23,768,099 20 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 13, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
263,158
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.